Guest Editorial Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA November 14, 2025Vol.51 No.42By Ellen V. Sigal
Regulatory News FDA to remove black box warnings on hormone therapy for menopauseTrump-era “gold standard science” is not to be confused with gold standard of scientific evidence November 14, 2025Vol.51 No.42By Claire Marie Porter
Trials & Tribulations Smoldering multiple myeloma: Rethinking the waiting game November 14, 2025Vol.51 No.42By C. Ola Landgren
Regulatory News CDER Director Tidmarsh quits amid inspector general probe of his “personal conduct”Cancer advocates express concern about comments that signal trouble for accelerated approval November 07, 2025Vol.51 No.41By Claire Marie Porter and Paul Goldberg
Guest Editorial How George Tidmarsh crossed the FDA-industry Rubicon November 07, 2025Vol.51 No.41By Mikkael A. Sekeres
Cancer Policy Zongertinib, dostarlimab chosen in second batch of National Priority Vouchers recipients November 07, 2025Vol.51 No.41By Jacquelyn Cobb
Drugs & Targets FDA approves Darzalex Faspro for high-risk smoldering multiple myeloma November 07, 2025Vol.51 No.41
Friends publishes three white papers ahead of annual meetingTopics: Clinical trials on rare cancers, combination drug trials, multi-regional studies October 31, 2025Vol.51 No.40By Sara Willa Ernst
